|
|
Vaccine Detail
|
secPD-L1 |
| Vaccine Information |
- Vaccine Name: secPD-L1
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Immunization Route: Other
- Description: secPD-L1 is a splice variant of PD-L1 (programmed death ligand-1, an immune checkpoint pathway) that does not splice into the transmembrane domain, but instead produces a secreted form of PD-L1 that has a unique 18 amino acid tail containing a cysteine that allows it to homodimerize and more effectively inhibit lymphocyte function than monomeric soluble PD-L1. Recombinant secPD-L1 can dimerize and inhibit T-cell proliferation and IFN-gamma production in vitro. SecPD-L1 may function as a paracrine negative immune regulator within the tumor, since secPD-L1 does not require a cell-to-cell interaction to mediate its inhibitory effect. This could lead to improved survival for patients with numerous types of cancers, including lung cancer, melanoma, renal cell carcinoma, and Hodgkin lymphoma. (Mahoney et al., 2019)
|
| Host Response |
|
|
| References |
Mahoney et al., 2019: Mahoney KM, Shukla SA, Patsoukis N, Chaudhri A, Browne EP, Arazi A, Eisenhaure TM, Pendergraft WF 3rd, Hua P, Pham HC, Bu X, Zhu B, Hacohen N, Fritsch EF, Boussiotis VA, Wu CJ, Freeman GJ. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer immunology, immunotherapy : CII. 2019; 68(3); 421-432. [PubMed: 30564891].
|
|
